In 2022, 175 females per 100,000 population were registered in England as newly diagnosed with breast cancer. This was an overall increase in comparison to the last few years' rate of registration. This statistic shows the rate of newly diagnosed female cases of breast cancer per 100,000 population in England from 1995 to 2022.

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

Cancer diagnoses and age-standardised incidence rates for all types of cancer by age and sex including breast, prostate, lung and colorectal cancer.

Deaths from breast cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

This publication reports on newly diagnosed cancers registered in England during 2021. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registrations (incidence) are provided by: Diagnosis (ICD-10 3-digit codes) by gender, age group, geographic region, deprivation and stage at diagnosis for selected cancer sites Diagnosis (ICD-10 4-digit code) by gender and age group

Years of Life Lost (YLL) as a result of death from breast cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

This statistic presents the share of women who have never been screened for breast cancer in England in 2022, by age group. Of women aged between 45 and 49 years, 98.6 percent have never been screened for breast cancer.

This data package contains information on cancer its type, its occurrence by age, type and site. It also provides detailed data on adult and childhood cancer survival rates and deaths caused by breast cancer in females.

Legacy unique identifier: P00154

This statistic shows the registrations of newly diagnosed cases of female breast cancer in England from 1995 to 2022. Breast cancer occurs when cells in the breast begin to grown abnormally, these cells often form a tumor. In 2022, over 50 thousand new cases were reported. The increase in cases since 1995 could also be due to more effective and frequent screening of women in England.

Proportion of women (age 53-70) offered screening for breast cancer by borough. Women between the ages of 50 and 70 are invited for regular breast screening (every three years) under a national programme. This is intended to detect breast cancer at an early stage. Click here to find out how to access historical data from The Health Needs Assessment toolkit as well as how to access more recent data.

IntroductionThe COVID-19 pandemic had collateral effects on many health systems. Cancer screening and diagnostic tests were postponed, resulting in delays in diagnosis and treatment. This study assessed the impact of the pandemic on screening, diagnostics and incidence of breast, colorectal, lung, and prostate cancer; and whether rates returned to pre-pandemic levels by December, 2021.MethodsThis is a cohort study of electronic health records from the United Kingdom (UK) primary care Clinical Practice Research Datalink (CPRD) GOLD database. The study included individuals registered with CPRD GOLD between January, 2017 and December, 2021, with at least 365 days of clinical history. The study focused on screening, diagnostic tests, referrals and diagnoses of first-ever breast, colorectal, lung, and prostate cancer. Incidence rates (IR) were stratified by age, sex, and region, and incidence rate ratios (IRR) were calculated to compare rates during and after lockdown with rates before lockdown. Forecasted rates were estimated using negative binomial regression models.ResultsAmong 5,191,650 eligible participants, the first lockdown resulted in reduced screening and diagnostic tests for all cancers, which remained dramatically reduced across the whole observation period for almost all tests investigated. There were significant IRR reductions in breast (0.69 [95% CI: 0.63-0.74]), colorectal (0.74 [95% CI: 0.67-0.81]), and prostate (0.71 [95% CI: 0.66-0.78]) cancer diagnoses. IRR reductions for lung cancer were non-significant (0.92 [95% CI: 0.84-1.01]). Extrapolating to the entire UK population, an estimated 18,000 breast, 13,000 colorectal, 10,000 lung, and 21,000 prostate cancer diagnoses were missed from March, 2020 to December, 2021.DiscussionThe UK COVID-19 lockdown had a substantial impact on cancer screening, diagnostic tests, referrals, and diagnoses. Incidence rates remained significantly lower than pre-pandemic levels for breast and prostate cancers and associated tests by December, 2021. Delays in diagnosis are likely to have adverse consequences on cancer stage, treatment initiation, mortality rates, and years of life lost. Urgent strategies are needed to identify undiagnosed cases and address the long-term implications of delayed diagnoses.

The proportion of women eligible for screening who have had a test with a recorded result at least once in the previous 36 months.RationaleBreast screening supports early detection of cancer and is estimated to save 1,400 lives in England each year. This indicator provides an opportunity to incentivise screening promotion and other local initiatives to increase coverage of breast screening.Improvements in coverage would mean more breast cancers are detected at earlier, more treatable stages.Breast screening supports early detection of cancer and is estimated to save 1,400 lives in England each year. This indicator provides an opportunity to incentivise screening promotion and other local initiatives to increase coverage of breast screening.Improvements in coverage would mean more breast cancers are detected at earlier, more treatable stages.Definition of numeratorTested women (numerator) is the number of eligible women aged 53 to 70 registered with a GP with a screening test result recorded in the past 36 months.Definition of denominatorEligible women (denominator) is the number of women aged 53 to 70 years resident in the area (determined by postcode of residence) who are eligible for breast screening at a given point in time, excluding those whose recall has been ceased for clinical reasons (for example, due to previous bilateral mastectomy).CaveatsData for ICBs are estimated from local authority data. In most cases ICBs are coterminous with local authorities, so the ICB figures are precise. In cases where local authorities cross ICB boundaries, the local authority data are proportionally split between ICBs, based on population located in each ICB.The affected ICBs are:Bath and North East Somerset, Swindon and Wiltshire;Bedfordshire, Luton and Milton Keynes;Buckinghamshire, Oxfordshire and Berkshire West;Cambridgeshire and Peterborough;Frimley;Hampshire and Isle of Wight;Hertfordshire and West Essex;Humber and North Yorkshire;Lancashire and South Cumbria;Norfolk and Waveney;North East and North Cumbria;Suffolk and North East Essex;Surrey Heartlands;Sussex;West Yorkshire.Please be aware that the April 2019 to March 2020, April 2020 to March 2021 and April 2021 to March 2022 data covers the time period affected by the COVID19 pandemic and therefore data for this period should be interpreted with caution.This indicator gives screening coverage by local authority . This is not the same as the indicator based on population registered with primary care organisations which include patients wherever they live. This is likely to result in different England totals depending on selected (registered or resident) population footprint.The indicator excludes women outside the target age range for the screening programme who may self refer for screening.Standards say "Women who are ineligible for screening due to having had a bilateral mastectomy, women who are ceased from the programme based on a ‘best interests’ decision under the Mental Capacity Act 2005 or women who make an informed choice to remove themselves from the screening programme will be removed from the numerator and denominator.There are a number of categories of women in the eligible age range who are not registered with a GP and subsequently not called for screening as they are not on the Breast Screening Select (BS Select) database. Screening units have a responsibility to maximise coverage of eligible women in their target population and should therefore be accessible to women in this category through self referral and GP referral ."This indicator gives screening coverage by local authority . This is not the same as the indicator based on population registered with primary care organisations which include patients wherever they live. This is likely to result in different England totals depending on selected (registered or resident) population footprint.

Legacy unique identifier: P00147

Background Information regarding the characteristics and health of women who do and do not attend for breast cancer screening is limited and representative data are difficult to obtain. Methods Information on age, deprivation and prescriptions for various medications was obtained for all women at two UK general practices who were invited to breast cancer screening through the National Health Service Breast Screening Programme. The characteristics of women who attended and did not attend screening were compared. Results Of the 1064 women invited to screening from the two practices, 882 (83%) attended screening. Screening attenders were of a similar age to non-attenders but came from significantly less deprived areas (30% of attenders versus 50% of non-attenders came from the most deprived areas, P < 0.0001) and were more likely to have a current prescription for hormone replacement therapy (32% versus 19%, P < 0.0001). No significant differences in recent prescriptions of medication for hypertension, heart disease, hypercholesterolaemia, diabetes mellitus, asthma, thyroid disease or depression/anxiety were observed between attenders and non-attenders. Conclusion Women who attend the National Health Service Breast Screening Programme come from less deprived areas and are more likely to have a current prescription for hormone replacement therapy than non-attenders, but do not differ in terms of age or recent prescriptions for various other medications.

BackgroundThere are striking differences in breast cancer incidence between Asian and western women. Rates vary substantially within Asia also, with Mongolia's even lower than China's. These profound differences have been speculated to be due in part to diet, mediated by circulating hormone concentrations.MethodsSex steroid hormone concentrations were measured in women living in Ulaanbaatar, Mongolia and the United Kingdom (U.K.). Diet was obtained by interview and national survey data. Mean hormone differences were compared by country, and systematic variation by number of days since last menstrual period was modeled and adjusted for age and parity; difference in overall area under the curves was assessed.FindingsThe diet in Mongolia was higher in meat and dairy than in the U.K. Mean testosterone concentrations were 18.5% lower (p

National Cancer Registration And Analysis Service (NCRAS). (2020). Cancer Registration: Incidence of female breast cancer in London (2002 - 2017) [Data set]. Public Health England. https://doi.org/10.25503/ex4h-zb30 This data set contains the incidence of female breast cancer (C50x, D05x) diagnosed in London, England between the years 2002 to 2017. Variables included: - TUMOUR_PSEUDO_ID (project specific pseudonymised tumour identification number) - AGE_CAT (age at diagnosis; 3 age categories: =70) - CCG_CODE (code for Clinical Commissioning Group (CCG) of patient residence) - CCG_NAME (name for CCG of patient residence) - DIAGNOSISMONTH (month of diagnosis; values range from 1 (January) to 12 (December)) - DIAGNOSISYEAR (year of diagnosis) - BEHAVIOUR_CODE_DESC (description of tumour behaviour code; 2 values: in situ and malignant) - RANK_VAR (differentiates between first and subsequent relevant tumours (for each patient); 2 values: first and subsequent) Whenever it is possible and practicable to do so, data released by PHE will be anonymous and made available under an Open Government License. To render the data anonymous it must be stripped of direct identifiers and privacy by design methods applied in line with the rules laid out in the ISB Anonymisation Standard for Publishing Health and Social Care Data Specification (2013).

Short-term variations in breast cancer deaths at different ages in England from 2020 to 2022, with 95% credible intervals.

Context

National Cancer Registration And Analysis Service (NCRAS). (2020). Cancer Registration: Incidence of female breast cancer in London (2002 - 2017) [Data set]. Public Health England. https://doi.org/10.25503/ex4h-zb30

This data set contains the incidence of female breast cancer (C50x, D05x) diagnosed in London, England between the years 2002 to 2017. https://data.gov.uk/dataset/3a1db673-f23d-4297-8274-cae4e9958c30/cancer-registration-incidence-of-female-breast-cancer-in-london-2002-2017

Content

Variables included: - TUMOURPSEUDOID (project specific pseudonymised tumour identification number) - AGECAT (age at diagnosis; 3 age categories: <40, 40-69, and >=70) - CCGCODE (code for Clinical Commissioning Group (CCG) of patient residence) - CCGNAME (name for CCG of patient residence) - DIAGNOSISMONTH (month of diagnosis; values range from 1 (January) to 12 (December)) - DIAGNOSISYEAR (year of diagnosis) - BEHAVIOURCODEDESC (description of tumour behaviour code; 2 values: in situ and malignant) - RANKVAR (differentiates between first and subsequent relevant tumours (for each patient); 2 values: first and subsequent)

Acknowledgements

http://www.ncin.org.uk/item?rid=4159 Creator: Julia Brown

https://data.gov.uk/dataset/3a1db673-f23d-4297-8274-cae4e9958c30/cancer-registration-incidence-of-female-breast-cancer-in-london-2002-2017

Photo by Peter Boccia on Unsplash

Inspiration

October - Breast cancer Awareness Month (Pink October).

This presents the latest one- and five-year age-standardised relative survival rates for cancers of the bladder, breast (in women), cervix, colon, lung, oesophagus, prostate and stomach with data for the government office regions (GOR) and strategic health authorities (SHA). Source agency: Office for National Statistics Designation: National Statistics Language: English Alternative title: Cancer survival in England by Health Authority